Premium
Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome – a report from the SFCE & CCLG groups
Author(s) -
Shankar Ananth G.,
Roques Gaelle,
Kirkwood Amy A.,
Lambilliotte Anne,
Freund Katja,
Leblanc Thierry,
Hayward Janis,
Abbou Samuel,
Ramsay Alan D.,
Schmitt Claudine,
GordeGrosjean Stephanie,
Pacquement Hélène,
Haouy Stephanie,
Boudjemaa Sabah,
Aladjidi Nathalie,
Hall Georgina W.,
LandmanParker Judith
Publication year - 2017
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14518
Subject(s) - medicine , rituximab , stage (stratigraphy) , chemotherapy , lymphoma , radiation therapy , oncology , surgery , gastroenterology , paleontology , biology
Summary Advanced stage nodular lymphocyte predominant Hodgkin lymphoma ( nLPHL ) is extremely rare in children and as a consequence, optimal treatment for this group of patients has not been established. Here we retrospectively evaluated the treatments and treatment outcomes of 41 of our patients from the UK and France with advanced stage nLPHL . Most patients received chemotherapy, some with the addition of the anti CD 20 antibody rituximab or radiotherapy. Chemotherapy regimens were diverse and followed either classical Hodgkin lymphoma or B non‐Hodgkin lymphoma protocols. All 41 patients achieved a complete remission with first line treatment and 40 patients are alive and well in remission. Eight patients subsequently relapsed and 1 patient died of secondary cancer (9 progression‐free survival events). The median time to progression for those who progressed was 21 months (5·9–73·8). The median time since last diagnosis is 87·3 months (8·44–179·20). Thirty‐six (90%), 30 (75%) and 27 (68%) patients have been in remission for more than 12, 24 and 36 months, respectively. Overall, the use of rituximab combined with multi‐agent chemotherapy as first line treatment seems to be a reasonable therapeutic option.